华氏巨球蛋白血症的诊断与管理——英国血液学学会指南
本指南由英国血液学学会(BSH)制定,基于2013年至2021年11月的文献检索,采用GRADE分级评估证据与推荐强度,为华氏巨球蛋白血症患者的管理提供明确指导,并涵盖IgM相关神经病、冷凝集素病、冷球蛋白血症等特殊情况。
要点
- 指南依据GRADE系统评估证据质量与推荐强度。
- 推荐基于2013年至2021年11月的文献复习。
- 涵盖华氏巨球蛋白血症及相关IgM疾病的管理。
核心结论
- 本指南为医疗专业人员提供华氏巨球蛋白血症患者管理的明确指导;个体患者的具体情况可能需采用替代方案。
研究设计与样本
- 本指南由英国血液学学会(BSH)按照其既定流程制定,文献检索覆盖Medline、Pubmed、Embase、Central、Web of Science从2013年初至2021年11月,采用GRADE分级系统评估证据等级和推荐强度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SCOPE: The objective of this guideline is to provide healthcare professionals with clear guidance on the management of patients with Waldenström macroglobulinaemia. In individual patients, circumstances may dictate an alternative approach. METHODOLOGY: This guideline was compiled according to the British Society for Haematology (BSH) process at http://www.b-s-h.org.uk/guidelines/proposing-and-writing-a-new-bsh-guideline/. Recommendations are based on a review of the literature using Medline, Pubmed, Embase, Central, Web of Science searches from beginning of 2013 (since the publication of the previous guidelines) up to November 2021. The following search terms were used: Waldenström('s) macroglobulin(a)emia OR lymphoplasmacytic lymphoma, IgM(-related) neuropathy OR cold h(a)emagglutinin disease OR cold agglutinin disease OR cryoglobulin(a)emia AND (for group a only) cytogenetic OR molecular OR mutation OR MYD88 OR CXCR4, management OR treatment OR transfusion OR supportive care OR plasma exchange OR plasmapheresis OR chemotherapy OR bendamustine OR bortezomib OR ibrutinib OR fludarabine OR dexamethasone OR cyclophosphamide OR rituximab OR everolimus, bone marrow transplantation OR stem cell transplantation. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) nomenclature was used to evaluate levels of evidence and to assess the strength of recommendations. The GRADE criteria can be found at http://www.gradeworkinggroup.org. Review of the manuscript was performed by the British Society for Haematology (BSH) Guidelines Committee Haemato-Oncology Task Force, the BSH Guidelines Committee and the Haemato-Oncology sounding board of BSH. It was also on the members section of the BSH website for comment. It has also been reviewed by UK Charity WMUK; these organisations do not necessarily approve or endorse the contents.
引用
- Pratt G, El-Sharkawi D, Kothari J, et al. Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline. Br J Haematol. 2022. PMID: 35020191. doi:10.1111/bjh.18036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。